Cargando…

Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review

RATIONALE: Hepatocellular carcinoma (HCC) metastases to the zygomatic bone are extremely uncommon, and the treatment of target drugs against such case is unknown. PATIENT CONCERNS: A 48-year-old male patient was admitted to our hospital under suspicion of an advanced liver tumor due to an increase i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Qiucheng, Chen, Huanwei, Zheng, Huazhen, Deng, Feiwen, Wang, Fengjie, Li, Jieyuan, Hu, Jianyuan, Fu, Rongdang, Zhen, Zuojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504308/
https://www.ncbi.nlm.nih.gov/pubmed/31045756
http://dx.doi.org/10.1097/MD.0000000000014595
_version_ 1783416549038620672
author Lei, Qiucheng
Chen, Huanwei
Zheng, Huazhen
Deng, Feiwen
Wang, Fengjie
Li, Jieyuan
Hu, Jianyuan
Fu, Rongdang
Zhen, Zuojun
author_facet Lei, Qiucheng
Chen, Huanwei
Zheng, Huazhen
Deng, Feiwen
Wang, Fengjie
Li, Jieyuan
Hu, Jianyuan
Fu, Rongdang
Zhen, Zuojun
author_sort Lei, Qiucheng
collection PubMed
description RATIONALE: Hepatocellular carcinoma (HCC) metastases to the zygomatic bone are extremely uncommon, and the treatment of target drugs against such case is unknown. PATIENT CONCERNS: A 48-year-old male patient was admitted to our hospital under suspicion of an advanced liver tumor due to an increase in levels of alpha-fetoprotein (AFP) after radiofrequency ablation for independent nodule in his liver 1 month before. He had a hepatitis B virus (HBV) history for 20 years without treatment. DIAGNOSIS AND INTERVENTIONS: A diagnosis of primary HCC was made based on pathological examination following right hepatectomy. Seven months after the surgery, a mass in S8 was identified and treated by ARF. Twenty days later, a right zygomatic mass was observed and the incisional biopsy revealed metastasis from HCC. Due to side effects of chemotherapy, the metastatic zygomatic mass was treated with radioactive seed implantation. Despite these interventions, there was steady increase in AFP values as well as increase in size of the zygomatic mass. Hence, the patient was started on apatinib with a dose of 500 mg/day from 1 to 28 days per cycle for a duration of 10 months. OUTCOMES: The AFP values were significantly decreased but the size of the zygomatic mass continued to increase indicating progression of disease. But the progression-free survival was more than 10 months. The patient exhibited adverse reactions which were controllable by symptomatic treatments. As of last follow-up, the patient is unwell with pain in the face, blurred vision in the right eye, dyscrasia, and exhibited difficulty in opening his mouth. LESSONS: HCC metastases to the zygomatic bone are very aggressive with a very low incidence and immunohistochemistry is useful diagnostic indicators. Still now, there is no optimal treatment strategy for these patients. Apatinib may be a promising drug in the treatment of HCC metastases to the zygomatic bone.
format Online
Article
Text
id pubmed-6504308
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-65043082019-05-29 Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review Lei, Qiucheng Chen, Huanwei Zheng, Huazhen Deng, Feiwen Wang, Fengjie Li, Jieyuan Hu, Jianyuan Fu, Rongdang Zhen, Zuojun Medicine (Baltimore) Research Article RATIONALE: Hepatocellular carcinoma (HCC) metastases to the zygomatic bone are extremely uncommon, and the treatment of target drugs against such case is unknown. PATIENT CONCERNS: A 48-year-old male patient was admitted to our hospital under suspicion of an advanced liver tumor due to an increase in levels of alpha-fetoprotein (AFP) after radiofrequency ablation for independent nodule in his liver 1 month before. He had a hepatitis B virus (HBV) history for 20 years without treatment. DIAGNOSIS AND INTERVENTIONS: A diagnosis of primary HCC was made based on pathological examination following right hepatectomy. Seven months after the surgery, a mass in S8 was identified and treated by ARF. Twenty days later, a right zygomatic mass was observed and the incisional biopsy revealed metastasis from HCC. Due to side effects of chemotherapy, the metastatic zygomatic mass was treated with radioactive seed implantation. Despite these interventions, there was steady increase in AFP values as well as increase in size of the zygomatic mass. Hence, the patient was started on apatinib with a dose of 500 mg/day from 1 to 28 days per cycle for a duration of 10 months. OUTCOMES: The AFP values were significantly decreased but the size of the zygomatic mass continued to increase indicating progression of disease. But the progression-free survival was more than 10 months. The patient exhibited adverse reactions which were controllable by symptomatic treatments. As of last follow-up, the patient is unwell with pain in the face, blurred vision in the right eye, dyscrasia, and exhibited difficulty in opening his mouth. LESSONS: HCC metastases to the zygomatic bone are very aggressive with a very low incidence and immunohistochemistry is useful diagnostic indicators. Still now, there is no optimal treatment strategy for these patients. Apatinib may be a promising drug in the treatment of HCC metastases to the zygomatic bone. Wolters Kluwer Health 2019-05-03 /pmc/articles/PMC6504308/ /pubmed/31045756 http://dx.doi.org/10.1097/MD.0000000000014595 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Lei, Qiucheng
Chen, Huanwei
Zheng, Huazhen
Deng, Feiwen
Wang, Fengjie
Li, Jieyuan
Hu, Jianyuan
Fu, Rongdang
Zhen, Zuojun
Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review
title Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review
title_full Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review
title_fullStr Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review
title_full_unstemmed Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review
title_short Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review
title_sort zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: a case report and literature review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504308/
https://www.ncbi.nlm.nih.gov/pubmed/31045756
http://dx.doi.org/10.1097/MD.0000000000014595
work_keys_str_mv AT leiqiucheng zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview
AT chenhuanwei zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview
AT zhenghuazhen zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview
AT dengfeiwen zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview
AT wangfengjie zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview
AT lijieyuan zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview
AT hujianyuan zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview
AT furongdang zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview
AT zhenzuojun zygomaticbonemetastasisfromhepatocellularcarcinomaandthetherapeuticefficacyofapatinibacasereportandliteraturereview